


A Case of Stiff Person Syndrome Treated Using Intrathecal Baclofen

Pratik Paudel¹, Pritam Gurung², Manik Kumar Lama³, Sambardhan Dabadi⁴, Resha Shrestha⁵, Rakshya Gautam⁶, Basant Pant⁷



Date of submission: 7th August 2023

Date of acceptance: 29th September 2023

Date of publication: 15th October 2023

Abstract

Introduction: Stiff Person Syndrome is a rare autoimmune neurological disorder with chronic muscle spasms leading to chronic pain and debilitation.

Case Report: We describe a case of a 57-year-old man with the history of Diabetes mellitus type 1 diagnosed 15 years back with high-titer positive anti-GAD antibodies and poorly controlled blood sugar levels under highly dosed insulin treatment.

Conclusion: Intrathecal baclofen showed a marked improvement for the relief of spasticity with the choice of a baclofen pump for similar patients.

Key words: Stiff Person Syndrome, spasm, anti GAD antibodies, intrathecal, baclofen

Introduction

Stiff Person Syndrome (SPS) formally known as Stiff Man Syndrome is a rare central nervous system disease characterized by progressive rigidity of the truncal muscles, superimposed spasms, and an exquisite sensitivity to external stimuli¹. SPS was first described in 1956 as a new clinical entity by Moersch and Woltman in a series of 14 patients. The course of SPS may vary among several patients. Some present with slow progressive disease while others show acute exacerbations and may change from one phenotype to another. Circulating anti-glutamic acid decarboxylase (anti GAD) antibodies are thought to create a γ -aminobutyric acid (GABA) -scarce environment within the body². These antibodies, although orders of magnitude greater in SPS, are also associated

with type 1 Diabetes mellitus³. We describe a case of a 57-year-old man with the history of Diabetes mellitus type 1 diagnosed 15 years back with high-titer positive anti-GAD antibodies and poorly controlled blood sugar levels under highly dosed insulin treatment.

Case Description

A 57-year-old male with past history of diabetes, anemia and atrophic gastritis was admitted to our institute with history of chronic muscle spasms and pain in the left lower limb in the last 4 months. The pain manifesting initially in the left knee later progressed to the upper thigh. The onset of illness was 10 years back initially presenting with mild spasms over the ankles, then progressing to the trunk, then generalizing making him be bedridden. Performed anti-GAD antibody serum test showed highly positive titers (696 nmol/L, normal ≤ 0.02 nmol/L). In the past, the patient had been treated with muscle relaxants and diazepam bringing partial relief. The patient displayed poorly controlled sugar levels with insulin requirements up to 66 IU daily. In addition, the patient had gastrointestinal symptoms at times. Endoscopy done at the previous center, revealed atrophic gastritis and erosive esophagitis LA grade A. The treatment had been completed with marked improvements. Mild anemia had been observed in the past with hemoglobin levels rising after iron treatment.

Magnetic resonance imaging (MRI) study covering the whole spine including bilateral hip joints, showed a loss of cervical lordosis and multilevel disc dedications at C4-C5 level. A mild central to left paramedial disc protrusion indenting on the anterior thecae sac and causing mild stenosis of the left C4-C5 lateral recess was found, as well as L3-L4 disc desiccation with no definite neural compression. Brain MRI previously performed at another

Access this article online

Website: <https://www.nepjol.info/index.php/NJN>

DOI: <https://doi.org/10.3126/njn.v20i3.57438>

HOW TO CITE

Paudel P, Gurung P, Lama MK, Dabadi S, Shrestha R, Gautam R, Pant B. A Case of Stiff Person Syndrome Treated Using Intrathecal Baclofen. NJNS. 2023;20(3):59-61.



Address for correspondence:

Pritam Gurung

Department of Neurosurgery

Annapurna Neurological Institute And Allied Sciences, Maitighar, Kathmandu, Nepal

E-mail: preetamgurung@hotmail.com

Copyright © 2023 Nepalese Society of Neurosurgeons (NESON)

ISSN: 1813-1948 (Print), 1813-1956 (Online)



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.

center, revealed bilateral periventricular and deep white matter ischemic changes. A nerve conduction test done on bilateral lower limbs showed with features suggestive of motor neuropathy of the bilateral tibial nerves.

The patient was admitted and managed conservatively with antispasmodics, analgesics. Following, the patient showed marked improvement in pain and spasms with applied intrathecal baclofen. Therefore, the option for baclofen pump insertion was discussed with the patient.

Discussion

SPS as a mainly clinical diagnosis with chronic muscle spasms and pain, leading to decreased activity and debilitation. Up to 80% of SPS patients have an accompanying endocrinopathy, making other autoimmune disorders frequently related with SPS^{4,5}. Pernicious anemia, autoimmune thyroid disease, and insulin-dependent diabetic mellitus have comorbid frequencies of 5%, 10%, and 35–60%, respectively^{2, 6}. The physiology of SPS is associated with GABAergic neurotransmission. Gamma Aminobutyric Acid (GABA) is a primary neurotransmitter found in the brain and produced by insulin producing beta cells of the pancreas. GABA performs by reducing neuronal excitability by inhibiting nerve transmission. Anti-Glutamic Acid Decarboxylase antibody (ANTI-GAD) is directed against Glutamate Decarboxylase (GAD) which synthesizes GABA.

High level of circulating Anti-GAD in SPS hence inhibits GABA and causes progressive muscle spasms⁷.

Pathophysiologic similarities exist between SPS and type 1 diabetes, supporting the fact that in up to 80% of individuals with type 1 diabetes anti-GAD can be found at the time of diagnosis, although typically lower in titers than in SPS^{4, 8–11}.

Here, we present a case of SPS who significantly bettered. From bed-ridden presentation, while admitted to an improvement of support guided walking at discharge after conservative management. Baclofen is a muscle relaxant used in multiple conditions for muscle spasms caused by multiple sclerosis, spinal cord injuries and other neurological diseases. The intrathecal system for baclofen delivers to a specific target at the spinal cord. Candidates for intrathecal baclofen are patients with intractable spasticity and chronic pain uncontrollable by drug therapy only. Advantage of the intrathecal system is the direct administration to the cerebrospinal fluid (CSF), bringing the possibility to use less concentrated dosages of the drug and long-term titration. Treatment goal is to improve quality of life by decreasing spasticity with improved range of motion and reduced contractures.

Similar study conducted in India showed SPS correlation with anti-GAD¹². Other studies conducted in

Sweden and USA showed that immunoglobulin therapy as effective modality of treatment for SPS^{13,14}.

Conclusion

SPS is a rare neurological disorder, an autoimmune disease with high levels of ANTI-GAD antibodies associated with other endocrinopathies leading to progressive spasms and chronic pain with leading to decreased quality of life. Intrathecal Baclofen showed a marked improvement for the relief of spasticity with the choice of a Baclofen pump for similar patients.

Ethics and Consent

Ethical approval of case report is not needed in accordance with the local ethical guideline. Written informed consent was obtained from the patient to include the clinical details.

Conflicts of Interest

None of the authors have potential conflicts of interest to be disclosed.

References

1. C. Toro, D. M. Jacobowitz, and M. Hallett, "Stiff-man syndrome," *Seminars in neurology*, vol. 14, no. 2, pp. 154–158, 1994, doi: 10.1055/S-2008-1041073.
2. M. C. Dalakas, "Stiff person syndrome: advances in pathogenesis and therapeutic interventions," *Current treatment options in neurology*, vol. 11, no. 2, pp. 102–110, 2009, doi: 10.1007/S11940-009-0013-9.
3. A. W. Van Deutekom, R. J. Heine, and S. Simsek, "The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus," *Diabetic medicine: a journal of the British Diabetic Association*, vol. 25, no. 2, pp. 117–125, Feb. 2008, doi: 10.1111/J.1464-5491.2007.02316.X.
4. A. J. Espay and R. Chen, "Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome," *Muscle & nerve*, vol. 34, no. 6, pp. 677–690, Dec. 2006, doi: 10.1002/MUS.20653.
5. A. McKeon *et al.*, "Stiff-man syndrome and variants: clinical course, treatments, and outcomes," *Archives of neurology*, vol. 69, no. 2, pp. 230–238, Feb. 2012, doi: 10.1001/ARCHNEUROL.2011.991.
6. H. M. Meinck and P. D. Thompson, "Stiff man syndrome and related conditions," *Movement disorders: official journal of the Movement Disorder Society*, vol. 17, no. 5, pp. 853–866, 2002, doi: 10.1002/MDS.10279.

7. F. S. Stuart, M. Henry, and H. L. Holley, "The stiff-man syndrome: Report of a case," *Arthritis & Rheumatism*, vol. 3, no. 3, pp. 229–232, 1960, doi: 10.1002/art.1780030305.
8. P. J. Bingley, "Clinical applications of diabetes antibody testing," *The Journal of clinical endocrinology and metabolism*, vol. 95, no. 1, pp. 25–33, 2010, doi: 10.1210/JC.2009-1365.
9. N. Ujihara, K. Daw, R. Gianani, E. Boel, L. Yu, and A. C. Powers, "Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes," *Diabetes*, vol. 43, no. 8, pp. 968–975, 1994, doi: 10.2337/DIAB.43.8.968.
10. M. Solimena, F. Folli, R. Aparisi, G. Pozza, and P. De Camilli, "Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome," *The New England journal of medicine*, vol. 322, no. 22, pp. 1555–1560, May 1990, doi: 10.1056/NEJM199005313222202.
11. A. Saiz *et al.*, "Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association," *Brain : a journal of neurology*, vol. 131, no. Pt 10, pp. 2553–2563, 2008, doi: 10.1093/BRAIN/AWN183.
12. R. Yadav, N. Abrol, and S. Terebelo, "One in a Million: A Case Report of Stiff Person Syndrome," *Case Reports in Rheumatology*, vol. 2022, pp. 1–5, Jan. 2022, doi: 10.1155/2022/7741545.
13. P. M. Nguyen, D. D. Vu, K. D. Vu, H. T. Nguyen, and D. Van Nguyen, "Stiff Person Syndrome: A Case Report with Sudden Onset and Coexistence of Sero-Positive Antibodies to Glutamic Acid Decarboxylase and Anti-SOX1 Antibodies," *Case reports in neurology*, vol. 14, no. 2, pp. 237–244, 2022, doi: 10.1159/000523988.
14. P. Manes, P. K. Manes, S. M. Aslam, M. Varghese, and L. Elipulikattu, "Stiff-Person Syndrome: A Case Report," *Journal of Medical Cases*, vol. 7, no. 10, pp. 426–428, Sep. 2016, doi: 10.14740/jmc.v7i10.2619.